Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 11.18 as of 2026-09-19T00:16:08.446Z.
Consensus retrieved: 2026-09-10T04:00:29.208Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-19T00:16:08.446Z.
Quote observation: 2026-09-18T20:00:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d87599fee45101dbfbeecce4369c39c8263b47b1e558529bba81fc1ad4225725
Forward PE Ratio (11.18) = Dated Quote Price ($95.36) / Consensus Forward EPS ($8.53)
FORWARD PE RATIO
11.18
SECTOR MEDIAN · HEALTHCARE
18.84
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
-40.67%
vs the sector median at left
Zimmer Biomet Holdings, Inc.
Market Cap
$18.45B
Forward PE Ratio
11.18
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Zimmer Biomet Holdings, Inc. (ZBH) | $18.45B | 11.18 |
| Viatris Inc. (VTRS)vs › | $19.74B | 6.78 |
| Medpace Holdings, Inc. (MEDP)vs › | $17.09B | 34.79 |
| STERIS plc (STE)vs › | $19.98B | 18.30 |
| Revvity, Inc. (RVTY)vs › | $16.00B | 26.79 |
| United Therapeutics Corporation (UTHR)vs › | $21.00B | 18.92 |
| Solventum Corporation (SOLV)vs › | $15.38B | 12.41 |
| Exelixis, Inc. (EXEL)vs › | $14.67B | 16.61 |
| Tempus AI, Inc. (TEM)vs › | $13.64B | N/A |
| Charles River Laboratories International, Inc. (CRL)vs › | $13.39B | 24.57 |
Trailing P/E
23.2
reported TTM EPS
Forward P/E
11.2
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $8.53 implies +107.5% EPS growth vs the reported trailing $4.11.
At the dated quote price of $95.36, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $8.53 | $8.49 – $8.56 | 16 | 11.2x |
| 2027-12-31 | $9.07 | $8.85 – $9.42 | 16 | 10.5x |
| 2028-12-31 | $9.73 | $8.37 – $11.26 | 9 | 9.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
